N/A
Completed N=2
89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Glioblastoma Multiforme
Source: ClinicalTrials.gov NCT02410577 ↗Enrolled (actual)
2
Serious AEs
0.0%
Results posted
Mar 2019
Primary outcomePrimary: Binding of 89Zr-J591
Summary
The purpose of this study is to test a new imaging agent called 89Zr-J591 (stands for humanized antibody called J591, that is attached to a radioactive material called Zirconium-89) in patients with glioblastoma multiforme.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Binding of 89Zr-J591 |
— | — |
Eligibility Criteria
Inclusion Criteria
- Patient age > 25 years old and 2.5 mg/dL.
- AST (SGOT) >2.5x ULN.
- Bilirubin (total) >1.5x ULN.
- Serum calcium >11 mg/dL.
- Pregnant or breastfeeding (if a female is of childbearing potential, and unsure of pregnancy status, a standard pregnancy test should be done).
- If an initial biopsy demonstrates neoplasm other than GBM
- Presence of any other co-existing condition which, in the judgment of the investigator, might increase the risk to the subject.
- Presence of serious systemic illness, including: uncontrolled inter-current infection, uncontrolled malignancy, significant renal disease, or psychiatric/social situations, which might limit compliance with study requirements
- Prior treatment.
- Other serious illness (es), which might preclude completion of this, study or interfere with determination of causality of any adverse effects experienced in this study.
Data sourced from ClinicalTrials.gov (NCT02410577). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.